Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 10,564 matching trials from the live ClinicalTrials.gov search.

Filters: Cincinnati, Ohio Clear all

Conditions: Neoplasms, Malignant
Interventions: cabazitaxel, gemcitabine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Detroit, Michigan • Cincinnati, Ohio • Philadelphia, Pennsylvania + 1 more

Conditions: Injury of Anterior Cruciate Ligament
Interventions: aNMT Biofeedback, Sham Biofeedback, Neuromuscular Training; Other
Lead sponsor: Emory University; Other
Eligibility: 12 Years to 18 Years · Female only
Enrollment: 420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Flowery Branch, Georgia • Cincinnati, Ohio

Conditions: Contraception, Women at Risk for Pregnancy
Interventions: LevoCept; Drug
Lead sponsor: Sebela Women's Health Inc.; Industry
Eligibility: Up to 45 Years · Female only
Enrollment: 1,525 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2032
U.S. locations: 27
States / cities: Berkeley, California • Los Angeles, California • Sacramento, California + 20 more

Conditions: Irritable Bowel Syndrome
Interventions: LX1031 High Dose, LX1031 Low Dose, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 36
States / cities: Tucson, Arizona • Sherwood, Arkansas • Anaheim, California + 29 more

Conditions: Adrenocortical Carcinoma
Interventions: suramin, therapeutic hydrocortisone; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 65
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more

Conditions: Ulcerative Colitis
Interventions: Vedolizumab, Tofacitinib; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 36
States / cities: Dothan, Alabama • Sun City, Arizona • Los Angeles, California + 32 more

Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: oxaliplatin; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 73
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more

Conditions: Chronic Total Occlusion of Coronary Artery, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions: placebo + aspirin, clopidogrel + aspirin OR prasugrel + aspirin, XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS); Drug · Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 870 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 144
States / cities: Birmingham, Alabama • Fairhope, Alabama • Scottsdale, Arizona + 126 more

Conditions: Depressive Disorder, Major
Interventions: Rapastinel, Placebo; Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 658 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 66
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 56 more

Conditions: Parkinson's Disease, Tremor, Bradykinesia
Interventions: Automated Programming; Device
Lead sponsor: Great Lakes NeuroTechnologies Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Multiple Myeloma
Interventions: JNJ-79635322, Teclistamab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • Springdale, Arkansas + 38 more

Conditions: Sickle Cell Disease, Sickle Cell Anemia, Sickle Cell Disorders, Hemoglobin S Disease, Sickling Disorder Due to Hemoglobin S
Interventions: HQK-1001; Drug
Lead sponsor: HemaQuest Pharmaceuticals Inc.; Industry
Eligibility: 12 Years to 60 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 9
States / cities: Oakland, California • Miami, Florida • Augusta, Georgia + 6 more

Conditions: Irritable Bowel Syndrome With Diarrhea
Interventions: Eluxadoline, Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 76
States / cities: Huntsville, Alabama • Saraland, Alabama • Phoenix, Arizona + 66 more

Conditions: Brain and Central Nervous System Tumors
Interventions: questionnaire administration, study of high risk factors; Other · Procedure
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Menlo Park, California • Cincinnati, Ohio

Conditions: Leukemia
Interventions: filgrastim, cladribine, cytarabine, etoposide, methotrexate, mitoxantrone hydrochloride, therapeutic hydrocortisone, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2008
U.S. locations: 35
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 27 more

Conditions: Spasticity, Multiple Sclerosis
Interventions: arbaclofen, baclofen, Placebo; Drug
Lead sponsor: RVL Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 25
States / cities: Cullman, Alabama • Long Beach, California • Aurora, Colorado + 20 more

Conditions: Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma
Interventions: Anastrozole, Exemestane, Laboratory Biomarker Analysis, Letrozole, Quality-of-Life Assessment, Systemic Chemotherapy, Tamoxifen Citrate; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 5,018 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1435
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 881 more

Conditions: Asthma
Interventions: fluticasone propionate/salmeterol, fluticasone propionate, montelukast; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 80
States / cities: Ozark, Alabama • Tempe, Arizona • Little Rock, Arkansas + 67 more

Conditions: Tricuspid Regurgitation
Interventions: Intrepid™ TTVR System; Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more

Conditions: Hemophilia A
Interventions: PF-05280602; Biological
Lead sponsor: Catalyst Biosciences; Industry
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 9
States / cities: San Diego, California • New Haven, Connecticut • Chicago, Illinois + 3 more

Conditions: Angelman Syndrome
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 1 Day to 60 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 6
States / cities: San Diego, California • Boston, Massachusetts • Cincinnati, Ohio + 3 more

Conditions: Narcolepsy Type 2
Interventions: TAK-360, Placebo; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 31
States / cities: Auburn, Alabama • Chandler, Arizona • Chula Vista, California + 26 more

Conditions: Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions: Etelcalcetide, Cinacalcet, Oral Placebo, Intravenous Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 683 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 41
States / cities: Azusa, California • Bakersfield, California • Chula Vista, California + 37 more

Conditions: Head and Neck Cancer
Interventions: cetuximab, intensity-modulated radiation therapy; Biological · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 702 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2029
U.S. locations: 250
States / cities: Birmingham, Alabama • Tucson, Arizona • Auburn, California + 191 more

Search by objective public record fields.

Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor

Real-time Sensorimotor Feedback for Injury Prevention Assessed in Virtual Reality

Evaluation of the Efficacy, Safety, and Tolerability of LevoCept

Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome

S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy

XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)

Pilot Study for Automated Deep Brain Stimulation Programming

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

A Study of HQK-1001 in Patients With Sickle Cell Disease

Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use

Developing Interview Questions to Estimate Workplace Exposure to Electric and Magnetic Fields

Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Study Of Patients With Allergic Rhinitis And Asthma

TTVR Early Feasibility Study

Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia

Characterization of Angelman Syndrome

A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)

Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet

RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer